Literature DB >> 19328010

Emerging markets & emerging needs: developing countries vaccine manufacturers' perspective & its current status.

Suresh S Jadhav1, Manish Gautam, Sunil Gairola.   

Abstract

The success of vaccination has remained an important contribution towards public health in both industrialised and developing countries. However, there are still unmet public health needs in vaccine preventable diseases owing to issues related to affordability, supply, public awareness, research and development, intellectual property, skilled human resource, etc. Various global initiatives are being taken to tackle such issues. DCVMN, Developing Country Vaccine Manufacturers' Network, is one of such novel initiatives by developing countries, and is playing an important role in facilitating cheaper and quality vaccines to children of the world. DCVMN has become an international body for emerging vaccine manufacturers from the developing world. This manuscript provides an overview of DCVMN with respect to its origin, objectives, achievements, limitations and expectations.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19328010     DOI: 10.1016/j.biologicals.2009.02.009

Source DB:  PubMed          Journal:  Biologicals        ISSN: 1045-1056            Impact factor:   1.856


  3 in total

1.  Enhancing the work of the Department of Health and Human Services national vaccine program in global immunization: recommendations of the National Vaccine Advisory Committee: approved by the National Vaccine Advisory Committee on September 12, 2013.

Authors: 
Journal:  Public Health Rep       Date:  2014       Impact factor: 2.792

2.  Indian vaccine innovation: the case of Shantha Biotechnics.

Authors:  Justin Chakma; Hassan Masum; Kumar Perampaladas; Jennifer Heys; Peter A Singer
Journal:  Global Health       Date:  2011-04-20       Impact factor: 4.185

3.  Technology innovation for infectious diseases in the developing world.

Authors:  Anthony D So; Quentin Ruiz-Esparza
Journal:  Infect Dis Poverty       Date:  2012-10-25       Impact factor: 4.520

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.